Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.05
MYL's Cash to Debt is ranked lower than
96% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.34 vs. MYL: 0.05 )
Ranked among companies with meaningful Cash to Debt only.
MYL' s 10-Year Cash to Debt Range
Min: 0.02  Med: 1.36 Max: 44.56
Current: 0.05
0.02
44.56
Equity to Asset 0.42
MYL's Equity to Asset is ranked lower than
78% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. MYL: 0.42 )
Ranked among companies with meaningful Equity to Asset only.
MYL' s 10-Year Equity to Asset Range
Min: 0.19  Med: 0.63 Max: 0.92
Current: 0.42
0.19
0.92
Interest Coverage 4.06
MYL's Interest Coverage is ranked lower than
90% of the 389 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2854.00 vs. MYL: 4.06 )
Ranked among companies with meaningful Interest Coverage only.
MYL' s 10-Year Interest Coverage Range
Min: 0.83  Med: 3.59 Max: 9.19
Current: 4.06
0.83
9.19
F-Score: 6
Z-Score: 2.07
M-Score: -1.94
WACC vs ROIC
7.72%
9.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 15.74
MYL's Operating margin (%) is ranked higher than
73% of the 667 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.78 vs. MYL: 15.74 )
Ranked among companies with meaningful Operating margin (%) only.
MYL' s 10-Year Operating margin (%) Range
Min: 2.31  Med: 18.41 Max: 36
Current: 15.74
2.31
36
Net-margin (%) 10.85
MYL's Net-margin (%) is ranked higher than
68% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.89 vs. MYL: 10.85 )
Ranked among companies with meaningful Net-margin (%) only.
MYL' s 10-Year Net-margin (%) Range
Min: -3.53  Med: 14.33 Max: 26.04
Current: 10.85
-3.53
26.04
ROE (%) 15.95
MYL's ROE (%) is ranked higher than
74% of the 696 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. MYL: 15.95 )
Ranked among companies with meaningful ROE (%) only.
MYL' s 10-Year ROE (%) Range
Min: -14.72  Med: 14.19 Max: 29.99
Current: 15.95
-14.72
29.99
ROA (%) 4.98
MYL's ROA (%) is ranked higher than
56% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.32 vs. MYL: 4.98 )
Ranked among companies with meaningful ROA (%) only.
MYL' s 10-Year ROA (%) Range
Min: -2.47  Med: 7.85 Max: 18.43
Current: 4.98
-2.47
18.43
ROC (Joel Greenblatt) (%) 22.67
MYL's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.13 vs. MYL: 22.67 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MYL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 4.11  Med: 37.69 Max: 92.62
Current: 22.67
4.11
92.62
Revenue Growth (3Y)(%) 11.60
MYL's Revenue Growth (3Y)(%) is ranked higher than
62% of the 546 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. MYL: 11.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MYL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -6.1  Med: 15.55 Max: 54.5
Current: 11.6
-6.1
54.5
EBITDA Growth (3Y)(%) 11.30
MYL's EBITDA Growth (3Y)(%) is ranked higher than
60% of the 492 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. MYL: 11.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MYL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -20  Med: 11.85 Max: 107
Current: 11.3
-20
107
EPS Growth (3Y)(%) 24.20
MYL's EPS Growth (3Y)(%) is ranked higher than
77% of the 453 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. MYL: 24.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MYL' s 10-Year EPS Growth (3Y)(%) Range
Min: -28.8  Med: 11.80 Max: 110.4
Current: 24.2
-28.8
110.4
» MYL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

MYL Guru Trades in Q3 2014

Ray Dalio 57,106 sh (New)
Paul Tudor Jones 20,015 sh (+376.55%)
Louis Moore Bacon 435,000 sh (+335.00%)
Vanguard Health Care Fund 15,444,880 sh (+223.41%)
John Paulson 12,494,700 sh (+3.00%)
Pioneer Investments 282,805 sh (unchged)
Louis Moore Bacon 350,000 sh (unchged)
John Hussman 50,000 sh (unchged)
Steven Cohen Sold Out
Scott Black 199,406 sh (-1.25%)
Mario Gabelli 10,000 sh (-27.54%)
Jim Simons 465,200 sh (-28.67%)
First Eagle Investment 809,603 sh (-34.81%)
» More
Q4 2014

MYL Guru Trades in Q4 2014

Joel Greenblatt 673,287 sh (New)
Paul Tudor Jones 254,152 sh (+1169.81%)
Pioneer Investments 691,198 sh (+144.41%)
John Paulson 14,948,400 sh (+19.64%)
First Eagle Investment 841,779 sh (+3.97%)
Mario Gabelli 10,000 sh (unchged)
Louis Moore Bacon 200,000 sh (unchged)
John Hussman 50,000 sh (unchged)
Jim Simons Sold Out
Vanguard Health Care Fund 15,037,080 sh (-2.64%)
Ray Dalio 52,706 sh (-7.70%)
Scott Black 181,796 sh (-8.83%)
Louis Moore Bacon 36,196 sh (-91.68%)
» More
Q1 2015

MYL Guru Trades in Q1 2015

Steven Cohen 253,300 sh (New)
Tom Russo 5,850 sh (New)
Pioneer Investments 826,251 sh (+19.54%)
Vanguard Health Care Fund 15,891,898 sh (+5.68%)
Scott Black 187,570 sh (+3.18%)
Paul Tudor Jones 125,000 sh (unchged)
John Paulson 14,948,400 sh (unchged)
Mario Gabelli 10,000 sh (unchged)
John Hussman Sold Out
Ray Dalio Sold Out
Louis Moore Bacon Sold Out
First Eagle Investment 586,016 sh (-30.38%)
Paul Tudor Jones 109,447 sh (-56.94%)
Joel Greenblatt 16,021 sh (-97.62%)
» More
Q2 2015

MYL Guru Trades in Q2 2015

Louis Moore Bacon 210,000 sh (New)
Jim Simons 548,006 sh (New)
Eric Mindich 1,456,404 sh (New)
Kyle Bass 780,251 sh (New)
David Tepper 989,528 sh (New)
Larry Robbins 1,815,874 sh (New)
John Keeley 37,050 sh (New)
Steven Cohen 1,331,200 sh (+425.54%)
Mario Gabelli 33,250 sh (+232.50%)
John Paulson 21,913,061 sh (+46.59%)
Tom Russo 5,850 sh (unchged)
Vanguard Health Care Fund 15,891,898 sh (unchged)
George Soros 160,000 sh (unchged)
Joel Greenblatt Sold Out
First Eagle Investment Sold Out
Scott Black 185,573 sh (-1.06%)
Pioneer Investments 631,760 sh (-23.54%)
Paul Tudor Jones 12,766 sh (-88.34%)
» More
» Details

Insider Trades

Latest Guru Trades with MYL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Mylan NV

Vanguard Health Care Fund Comments on Mylan NV - Mar 27, 2015

We increased our position in this global generic pharmaceutical manufacturer as its core generic business remains steady and has benefited from selective price increases. We believe the planned acquisition of Abbott’s non-U.S. established pharmaceuticals business will augment the company’s globalization strategy.

From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report

Check out Vanguard Health Care Fund latest stock trades

Top Ranked Articles about Mylan NV

Kyle Bass Focuses on Fuel, Pharmaceutical Stocks in Second Quarter
If there was a theme to Kyle Bass (Trades, Portfolio)’ investment activity in the second quarter, the founder of Dallas-based Hayman Capital Management L.P., displayed an interest in fuel and pharmaceutical stocks. Not all of Bass’ transactions fit neatly into that category, of course, but many did, including most of the largest ones. Read more...
Tom Russo Buys 3 New Stocks in Q1
Tom Russo (Trades, Portfolio) added three new stocks to his portfolio during Q1, including an insurance and pharmaceutical company, according to GuruFocus Real Time Picks. Read more...
Vanguard Health Care Fund Comments on Mylan NV
We increased our position in this global generic pharmaceutical manufacturer as its core generic business remains steady and has benefited from selective price increases. We believe the planned acquisition of Abbott’s non-U.S. established pharmaceuticals business will augment the company’s globalization strategy. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 23.29
MYL's P/E(ttm) is ranked higher than
66% of the 479 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.40 vs. MYL: 23.29 )
Ranked among companies with meaningful P/E(ttm) only.
MYL' s 10-Year P/E(ttm) Range
Min: 7.05  Med: 23.57 Max: 112.56
Current: 23.29
7.05
112.56
Forward P/E 10.76
MYL's Forward P/E is ranked higher than
88% of the 232 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.58 vs. MYL: 10.76 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 23.60
MYL's PE(NRI) is ranked higher than
66% of the 477 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.40 vs. MYL: 23.60 )
Ranked among companies with meaningful PE(NRI) only.
MYL' s 10-Year PE(NRI) Range
Min: 7.05  Med: 23.70 Max: 200.11
Current: 23.6
7.05
200.11
P/B 2.63
MYL's P/B is ranked higher than
56% of the 644 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.12 vs. MYL: 2.63 )
Ranked among companies with meaningful P/B only.
MYL' s 10-Year P/B Range
Min: 0.64  Med: 2.67 Max: 7.02
Current: 2.63
0.64
7.02
P/S 2.66
MYL's P/S is ranked higher than
55% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.13 vs. MYL: 2.66 )
Ranked among companies with meaningful P/S only.
MYL' s 10-Year P/S Range
Min: 0.41  Med: 1.83 Max: 4.61
Current: 2.66
0.41
4.61
PFCF 61.13
MYL's PFCF is ranked lower than
65% of the 267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 42.27 vs. MYL: 61.13 )
Ranked among companies with meaningful PFCF only.
MYL' s 10-Year PFCF Range
Min: 8.81  Med: 19.77 Max: 89.33
Current: 61.13
8.81
89.33
POCF 22.53
MYL's POCF is ranked higher than
57% of the 387 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.20 vs. MYL: 22.53 )
Ranked among companies with meaningful POCF only.
MYL' s 10-Year POCF Range
Min: 6.09  Med: 12.68 Max: 40.56
Current: 22.53
6.09
40.56
EV-to-EBIT 26.05
MYL's EV-to-EBIT is ranked lower than
53% of the 488 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.19 vs. MYL: 26.05 )
Ranked among companies with meaningful EV-to-EBIT only.
MYL' s 10-Year EV-to-EBIT Range
Min: -10.7  Med: 16.70 Max: 35.3
Current: 26.05
-10.7
35.3
PEG 2.84
MYL's PEG is ranked lower than
54% of the 257 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.57 vs. MYL: 2.84 )
Ranked among companies with meaningful PEG only.
MYL' s 10-Year PEG Range
Min: 0.45  Med: 2.43 Max: 11.64
Current: 2.84
0.45
11.64
Shiller P/E 38.20
MYL's Shiller P/E is ranked lower than
53% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.90 vs. MYL: 38.20 )
Ranked among companies with meaningful Shiller P/E only.
MYL' s 10-Year Shiller P/E Range
Min: 10.98  Med: 25.28 Max: 701
Current: 38.2
10.98
701
Current Ratio 1.47
MYL's Current Ratio is ranked lower than
72% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. MYL: 1.47 )
Ranked among companies with meaningful Current Ratio only.
MYL' s 10-Year Current Ratio Range
Min: 1.28  Med: 3.43 Max: 8.52
Current: 1.47
1.28
8.52
Quick Ratio 1.11
MYL's Quick Ratio is ranked lower than
70% of the 617 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. MYL: 1.11 )
Ranked among companies with meaningful Quick Ratio only.
MYL' s 10-Year Quick Ratio Range
Min: 0.85  Med: 2.84 Max: 6.76
Current: 1.11
0.85
6.76
Days Inventory 143.00
MYL's Days Inventory is ranked lower than
64% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 112.66 vs. MYL: 143.00 )
Ranked among companies with meaningful Days Inventory only.
MYL' s 10-Year Days Inventory Range
Min: 88.95  Med: 147.43 Max: 175.9
Current: 143
88.95
175.9
Days Sales Outstanding 124.18
MYL's Days Sales Outstanding is ranked lower than
78% of the 598 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.39 vs. MYL: 124.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYL' s 10-Year Days Sales Outstanding Range
Min: 49.61  Med: 83.48 Max: 107.26
Current: 124.18
49.61
107.26

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.97
MYL's Price/Projected FCF is ranked higher than
63% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. MYL: 1.97 )
Ranked among companies with meaningful Price/Projected FCF only.
MYL' s 10-Year Price/Projected FCF Range
Min: 0.62  Med: 1.39 Max: 2.59
Current: 1.97
0.62
2.59
Price/DCF (Earnings Based) 3.01
MYL's Price/DCF (Earnings Based) is ranked lower than
75% of the 57 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.59 vs. MYL: 3.01 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.46
MYL's Price/Median PS Value is ranked lower than
60% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.28 vs. MYL: 1.46 )
Ranked among companies with meaningful Price/Median PS Value only.
MYL' s 10-Year Price/Median PS Value Range
Min: 0.36  Med: 1.94 Max: 3.77
Current: 1.46
0.36
3.77
Price/Peter Lynch Fair Value 2.41
MYL's Price/Peter Lynch Fair Value is ranked lower than
63% of the 158 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.79 vs. MYL: 2.41 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MYL' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.67  Med: 1.56 Max: 10.2
Current: 2.41
0.67
10.2
Earnings Yield (Greenblatt) (%) 3.84
MYL's Earnings Yield (Greenblatt) (%) is ranked higher than
63% of the 695 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. MYL: 3.84 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MYL' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 2.8  Med: 5.70 Max: 15.1
Current: 3.84
2.8
15.1
Forward Rate of Return (Yacktman) (%) 12.44
MYL's Forward Rate of Return (Yacktman) (%) is ranked higher than
60% of the 315 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.18 vs. MYL: 12.44 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MYL' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 3.6  Med: 6.40 Max: 39.2
Current: 12.44
3.6
39.2

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 9,726 10,622 11,192
EPS($) 4.21 4.78 5.25
EPS without NRI($) 4.21 4.78 5.25

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:0R5P.UK, MYL1.Switzerland, 6MY.Germany,
Mylan NV was incorporated in Pennsylvania in 1970. The Company together with its subsidiaries, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company offers 1,300 marketed products, to customers in 140 countries and territories. It also operates a research and development network that delivers a robust product pipeline. Additionally, the Company has a specialty business that is engaged in the respiratory and allergy therapies. It offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids while engaging on those products that are difficult to formulate and manufacture, and typically have longer life cycles than traditional generic pharmaceuticals, including transdermal patches, high potency formulations, injectables, controlled-release and respiratory products. In addition, it offers antiretroviral therapies upon which HIV/AIDS patients in developing countries depend. The Company operates in two segments, Generics and Specialty. The generic pharmaceutical business is conducted in the U.S. and Canada, Europe, the Middle East, and Africa and India, Australia, Japan, New Zealand and Brazil. The Generics segment develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages in the development, manufacture and sale of branded specialty nebulized and injectable products. The Company owns or licenses a number of patents in the U.S. and other countries covering certain products and have also developed brand names and trademarks for other products. In North America, the Company markets products directly to wholesalers, distributors, retail pharmacy chains, long-term care facilities, mail order pharmacies and GPOs. It also market its generic products indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, pharmacy benefit management companies and government entities. The Company's competitors include other generic companies and branded drug companies that continue to sell or license branded pharmaceutical products after patent expirations and other statutory expirations. In the branded space, key competitors are generally other branded drug companies that compete based on its clinical characteristics and benefits.
» More Articles for MYL

Headlines

Articles On GuruFocus.com
Kyle Bass Focuses on Fuel, Pharmaceutical Stocks in Second Quarter Aug 24 2015 
Taconic Capital Buys Time Warner Cable, Broadcom Aug 23 2015 
David Tepper Starts 3 New Substantial Positions in Second Quarter Aug 14 2015 
JFS Wealth Advisors LLC Buys Alliance Holdings in Q2 2015 Aug 05 2015 
KEELEY All Cap Value Fund First Quarter 2015 Commentary Jun 17 2015 
Actavis Stock – A Must Have For Long-Term Investors May 27 2015 
Tom Russo Buys 3 New Stocks in Q1 May 18 2015 
Teva Puts Forth Its Best Bid To Acquire Mylan Apr 25 2015 
Teva Eyeing Mylan For $40 Billion Apr 23 2015 
CalAmp and Illumina Significant Earnings Growth; Perrigo Rebuffs Takeover Offer Apr 22 2015 

More From Other Websites
Mylan Shareholders Back Hostile Bid For Perrigo Aug 28 2015
Mylan shareholders approve hostile takeover Aug 28 2015
Mylan shareholders back Perrigo takeover, tender offer up next Aug 28 2015
Mylan Investors Vote to Push Ahead With Hostile Perrigo Deal Aug 28 2015
Mylan shareholders approve pursuit of Perrigo Aug 28 2015
Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction Aug 28 2015
Mylan shareholders approve pursuit of Perrigo Aug 28 2015
Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction Aug 28 2015
Mylan shareholders approve acquisition of Perrigo Aug 28 2015
Early movers: BIG, MYL, FCX, BGS, FB, ADSK & more Aug 28 2015
Mylan says shareholders back Perrigo takeover Aug 28 2015
Mylan Holders Approve Perrigo Purchase Aug 28 2015
Mylan Launches Generic Version of Lidoderm® Patch Aug 28 2015
7:23 am Mylan Labs announces that shareholders have approved its proposed acquisition of Perrigo... Aug 28 2015
Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo Aug 28 2015
Expect Perrigo To Grow, With Or Without Hostile Mylan Aug 27 2015
Abbott denies $25bn bid for St Jude Aug 27 2015
Coverage initiated on Mylan Labs by Standpoint Research Aug 26 2015
Mylan Second Quarter 2015 Constant Currency Revenue Increases 36% and Adjusted Diluted EPS Increases... Aug 25 2015
Perrigo CEO Still Pursuing Deals Amid Takeover Feud With Mylan Aug 25 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK